Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

NCT06167694 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable or Metastatic Breast Cancer

Interventions

DRUG: HRS-8080; Dalpiciclib Isethionate Tablets

Sponsor

Shandong Suncadia Medicine Co., Ltd.